Eric Alton is Professor of Gene Therapy and Respiratory Medicine, National Heart & Lung Institute, Imperial College London and Honorary Consultant Physician, Royal Brompton Hospital
Professor Alton was educated at Jesus College, Cambridge and Westminster Medical School and subsequently undertook six years of general medical training. Over the last fifteen years, he has been involved in developing gene therapy for cystic fibrosis and angiogenesis, including three clinical trials.
Professor Alton coordinates the UK CF Gene Therapy Consortium which brings together the three centres in the UK (Edinburgh and Oxford Universities and Imperial College), including approximately 80 clinicians and scientists focused on this problem.
et al., 2016, Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung, Antimicrobial Agents and Chemotherapy, Vol:60, ISSN:0066-4804, Pages:744-751
Griesenbach U, Pytel KM, Alton EWFW, 2015, Cystic Fibrosis Gene Therapy in the UK and Elsewhere, Human Gene Therapy, Vol:26, ISSN:1043-0342, Pages:266-275
Griesenbach U, Alton EW, 2015, Recent advances in understanding and managing cystic fibrosis transmembrane conductance regulator dysfunction., F1000prime Rep, Vol:7
et al., 2015, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF REPEATED NEBULISATION OF NON-VIRAL CFTR GENE THERAPY IN PATIENTS WITH CYSTIC FIBROSIS, Pediatric Pulmonology, Vol:50, ISSN:8755-6863, Pages:262-262
et al., 2015, RESPIRATORY SYNCYTIAL VIRUS LEADS TO MORE RAPID CELL DEATH IN PHE508DEL BRONCHIAL EPITHELIAL CELLS, Pediatric Pulmonology, Vol:50, ISSN:8755-6863, Pages:314-315